Acute	acute	O	DISEASE	OTHERS	I
liver	liver	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
in	in	O	O	O	O
two	two	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
regular	regular	O	O	O	O
alcohol	alcohol	CHEMICALS	O	OTHERS	I
consumption	consumption	O	O	O	O
ingesting	ingesting	O	O	O	O
paracetamol	paracetamol	CHEMICALS	O	OTHERS	I
at	at	O	O	O	O
therapeutic	therapeutic	O	O	O	O
dosage	dosage	O	O	O	O
.	.	O	O	O	O

BACKGROUND	background	O	O	O	O
:	:	O	O	O	O
The	the	O	O	O	O
possible	possible	O	O	O	O
role	role	O	O	O	O
of	of	O	O	O	O
alcohol	alcohol	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
the	the	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
hepatotoxicity	hepatotoxicity	O	DISEASE	OTHERS	I
associated	associated	O	O	O	O
with	with	O	O	O	O
therapeutic	therapeutic	O	O	O	O
doses	doses	O	O	O	O
of	of	O	O	O	O
paracetamol	paracetamol	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
acetaminophen	acetaminophen	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
is	is	O	O	O	O
currently	currently	O	O	O	O
debated	debated	O	O	O	O
.	.	O	O	O	O

CASE	case	O	O	O	O
REPORT	report	O	O	O	O
:	:	O	O	O	O
We	we	O	O	O	O
describe	describe	O	O	O	O
2	2	O	O	O	O
patients	patients	O	O	O	O
who	who	O	O	O	O
were	were	O	O	O	O
regular	regular	O	O	O	O
consumers	consumers	O	O	O	O
of	of	O	O	O	O
alcohol	alcohol	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
who	who	O	O	O	O
developed	developed	O	O	O	O
liver	liver	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
within	within	O	O	O	O
3	3	O	O	O	O
-	-	O	O	O	O
5	5	O	O	O	O
days	days	O	O	O	O
after	after	O	O	O	O
hospitalization	hospitalization	O	O	O	O
and	and	O	O	O	O
stopping	stopping	O	O	O	O
alcohol	alcohol	CHEMICALS	O	OTHERS	I
consumption	consumption	O	O	O	O
while	while	O	O	O	O
being	being	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
4	4	O	O	O	O
g	g	O	O	O	O
paracetamol/day	paracetamol/day	O	O	O	O
.	.	O	O	O	O

A	a	O	O	O	O
paracetamol	paracetamol	CHEMICALS	O	OTHERS	I
serum	serum	O	O	O	O
level	level	O	O	O	O
obtained	obtained	O	O	O	O
in	in	O	O	O	O
one	one	O	O	O	O
of	of	O	O	O	O
these	these	O	O	O	O
patients	patients	O	O	O	O
was	was	O	O	O	O
not	not	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
toxic	toxic	O	O	O	O
range	range	O	O	O	O
.	.	O	O	O	O

Possible	possible	O	O	O	O
risk	risk	O	O	O	O
factors	factors	O	O	O	O
for	for	O	O	O	O
the	the	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
hepatotoxicity	hepatotoxicity	O	DISEASE	OTHERS	I
in	in	O	O	O	O
patients	patients	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
therapeutic	therapeutic	O	O	O	O
doses	doses	O	O	O	O
of	of	O	O	O	O
paracetamol	paracetamol	CHEMICALS	O	OTHERS	I
are	are	O	O	O	O
discussed	discussed	O	O	O	O
.	.	O	O	O	O

CONCLUSION	conclusion	O	O	O	O
:	:	O	O	O	O
In	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
risk	risk	O	O	O	O
factors	factors	O	O	O	O
,	,	O	O	O	O
e.g.	e.g.	O	O	O	O
regular	regular	O	O	O	O
consumption	consumption	O	O	O	O
of	of	O	O	O	O
alcohol	alcohol	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
liver	liver	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
is	is	O	O	O	O
possible	possible	O	O	O	O
when	when	O	O	O	O
therapeutic	therapeutic	O	O	O	O
doses	doses	O	O	O	O
are	are	O	O	O	O
ingested	ingested	O	O	O	O
.	.	O	O	O	O

We	we	O	O	O	O
propose	propose	O	O	O	O
that	that	O	O	O	O
the	the	O	O	O	O
paracetamol	paracetamol	CHEMICALS	O	OTHERS	I
dose	dose	O	O	O	O
should	should	O	O	O	O
not	not	O	O	O	O
exceed	exceed	O	O	O	O
2	2	O	O	O	O
g/day	g/day	O	O	O	O
in	in	O	O	O	O
such	such	O	O	O	O
patients	patients	O	O	O	O
and	and	O	O	O	O
that	that	O	O	O	O
their	their	O	O	O	O
liver	liver	O	O	O	O
function	function	O	O	O	O
should	should	O	O	O	O
be	be	O	O	O	O
monitored	monitored	O	O	O	O
closely	closely	O	O	O	O
while	while	O	O	O	O
being	being	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
paracetamol	paracetamol	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

